

Accel-Heal Technologies Limited Hever Business Centre, Hever Kent, TN8 7ER UK

05/10/2023

Confirmation Letter Reference: CLNB1639 GBPC 218938

To whom it may concern,

Confirmation of receipt of a formal application and conclusion of written agreement in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices

This letter confirms that, SGS Belgium NV, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number 1639 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

Accel-Heal Technologies Limited

Hever Business Centre, Hever Kent, TN8 7ER UK

SRN: GB-MF-000010881

EU representative:

Advena Limited.
Tower Business Centre,
2nd Floor, Tower Street,
Swatar, BKR 4013
Malta

SRN: MT-AR-000000234

The devices covered by the formal application and the written agreement mentioned above are shown at the end of this letter.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired prior to the publication of the Regulation EU 2023/607 on 15 March 2023, this letter also confirms that:

SGS Belgium NV

Certification and Business Enhancement Registered Office: Noorderlaan 87 BE-2030 Antwerpen t +32 (0)3 545 48 48 f +32 (0)3 545 48 49 Boulevard International/Internationalelaan 55D BE-1070 Brussels t+32 (0)2 556 00 40 f +32 (0)3 545 48 49 www.be.sgs.com



- the manufacturer submitted the MDR application and signed the written agreement by the date of MDD/AIMDD certificate expiry;
- the certificates expired after 26 May 2021 by course of time and were valid at the date of their expiry neither having been suspended nor withdrawn.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3 of MDR (as amended by EU 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Wellestablished technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

pp [Jérôme JADOT]

On behalf of the Notified Body SGS Belgium NV 1639,

Virginie SILORET

Global Medical Device Certification Manager

Email: Virginie.siloret@sgs.com Phone: +41 22 739 98 58





Devices covered by this letter:

Device name / Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the preapplication stage)	If the MDR device is a substitute device,identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
- Accel-Heal Non-sterile, single use microcurrent stimulation device for improved rate of wound healing 5060276100073R9	Class IIa	N/A	GB19/964796; NB1639

Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2023/10/05	Version 1	Initial issue
NB'		